4. Deferred Revenue

We expect our current deferred revenue to be recognized as revenue within 12 months. We expect the majority of our non-current deferred revenue to be recognized as revenue over a period of approximately three years from March 31, 2026. This period of time represents an estimate of the ongoing sample testing for our customers' therapeutic development efforts.

Changes in deferred revenue during the three months ended March 31, 2026 were as follows (in thousands):


Deferred revenue balance at December 31, 2025	$	46,200
Additions to deferred revenue during the period		19,583
Revenue recognized during the period		(15,579	)
Deferred revenue balance at March 31, 2026	$	50,204

During the three months ended March 31, 2026, $8.2 million was recognized as revenue that was included in the deferred revenue balance at December 31, 2025.